US Food and Drug Administration (FDA) has issued eight observations for Lupin’s Aurangabad unit, which was inspected between April 17 and 26, 2017. These observations pertain to some market complaints regarding contamination of the drug & its effect on the consumer, some data related issues and some manufacturing protocols not being followed.
Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.
